Ancillary Revenue Program - Are you still sending out these tests to an outside lab? UTI/STI • Vaginitis • Respiratory • ENT/Sinus • Wound • GI related infections. Find out how to CAPTURE OUTSIDE LAB REVENUE and improve patient experience and outcomes. (8) tests a day generates you over $30K in bottom-line revenue & advances patient care with a 1-hour test result that includes antibiotic resistance read-out.
https://optimalhealthadvocates.com/
UROLOGY • OB/GYN • INTERNAL MEDICINE • PRIMARY CARE • URGENT CARE • PEDIATRICS • ENT/ALLERGY • WOUND CARE
PROVEN PROGRAM:
✅ Over 100 Established Locations across the United States -- each generating at least $30K/month in bottom-line revenue.
✅ ELIMINATE delayed or ineffective antibiotic treatment & costly last-minute surgery cancellations (1-hour turn-around for results with antibiotic resistance read-out);
✅ Keep your providers compliant with CDC Antibiotic Stewardship Program (that is soon to be mandated in the clinical setting) with our program's monthly reports that will increase your facility health score by showing you are reducing the use of unnecessary antibiotics with PCR testing that is 96% more accurate than a traditional culture.
We handle ALL of the upfront capital costs, billing, staffing, and CLIA licensure/compliance at NO UPFRONT COST TO THE PRACTICE -- All that’s required is a 6-foot workspace to run the tests.
To LEARN MORE and SEE IF YOUR PRACTICE QUALIFIES, Book a 10-min Discovery Call with Jen here:
https://go.oncehub.com/Advanced_In-Office_PCR_Lab_Discovery-Call
Optimal Health Advocates as an Ancillary Medical Practice Revenue Generation company helping medical practices capture significant revenue increases while improving patient lives and outcomes.
--------------
Jennifer Anderson is a 20-year Practice Manager, entrepreneur, and digital marketing expert who intimately understands the challenges of the business of medicine and is passionate about helping Medical Sales Companies and Medical Practices successfully implement systems and services that enhance and save patient lives and increase practice revenue.
Objectives:
•Further to the launch of the revised SSI Getting Started Kit and improved measures, to introduce a new audit tool; Data Collection Form (DCF) and complementary data base which allows teams to collect patient level data on specific SSI prevention related process and outcome measures.
•To demonstrate how this data can be easily submitted and analyzed through the Patient Safety Metrics system and used to accelerate your quality improvement initiatives
WATCH: http://bit.ly/1GGtOpX
Accelerating the translation of medical research - 27 JuneInnovation Agency
Slides from the event focusing on translational research in Liverpool and North of England and why companies are establishing and growing operations in the region.
Provides information on rapid initiation of antiretroviral therapy (ART) regimen for patients with HIV, including clinical recommendations and key points regarding rational, protocol, general principles, and payment.
Find more information at https://www.hivguidelines.org/antiretroviral-therapy/rapid-art/
Sponsored by the New York State Department of Health (NYSDOH) AIDS Institute (AI) and the HIV Clinical Guidelines Program
1.To discuss:
•strategies to engage physicians in medication reconciliation
•the benefits of medication reconciliation from the perspective of physicians
•physician roles in the medication reconciliation process
2.To provide an opportunity for teams to discuss their MedRec questions and challenges with a panel of physicians
Objectives:
•Further to the launch of the revised SSI Getting Started Kit and improved measures, to introduce a new audit tool; Data Collection Form (DCF) and complementary data base which allows teams to collect patient level data on specific SSI prevention related process and outcome measures.
•To demonstrate how this data can be easily submitted and analyzed through the Patient Safety Metrics system and used to accelerate your quality improvement initiatives
WATCH: http://bit.ly/1GGtOpX
Accelerating the translation of medical research - 27 JuneInnovation Agency
Slides from the event focusing on translational research in Liverpool and North of England and why companies are establishing and growing operations in the region.
Provides information on rapid initiation of antiretroviral therapy (ART) regimen for patients with HIV, including clinical recommendations and key points regarding rational, protocol, general principles, and payment.
Find more information at https://www.hivguidelines.org/antiretroviral-therapy/rapid-art/
Sponsored by the New York State Department of Health (NYSDOH) AIDS Institute (AI) and the HIV Clinical Guidelines Program
1.To discuss:
•strategies to engage physicians in medication reconciliation
•the benefits of medication reconciliation from the perspective of physicians
•physician roles in the medication reconciliation process
2.To provide an opportunity for teams to discuss their MedRec questions and challenges with a panel of physicians
Digital Solutions putting the patient at the forefront of Risk ManagementMyMeds&Me
Capturing relevant, essential and complete data at the first interaction
Why surfacing targeted questions and FAQs in-stream maximises the value of the initial contact and reduces low-value follow up.
Digital solutions ensure your REMS and RMP commitments are met with appropriate evidence
Quality Control for Point of Care Testing - White PaperRandox
Point of care testing (POCT) refers to testing that is performed near or at the site of a patient with the result leading to a possible change in the care of the patient. Over the past few years, the popularity and demand of POCT has been growing rapidly. This should come as no surprise as there are many advantages to POCT, for example, the added convenience of being able to obtain a rapid result at the patient’s bedside, thus allowing immediate action, saving time and improving the potential outcome for the patient.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Customized Oncology Development Solutions: Clinical Trials Designed Around You®Covance
Oncology is one of the most research-intensive therapeutic areas, yet no two development programs are the same. No two trials are the same. Each one calls for a customized strategy and distinct trial management approach. Covance develops fit-for-purpose solutions Designed Around You® that enable more efficient clinical trials and focus on what is most valuable to your organization.
POINT-of-IMPACT testing. A European perspective - Bert NiestersWAidid
At SoGat meeting 2019 Bert Niesters - Professor in Molecular Diagnostic in Clinical Virology, Medical Molecular Microbiologist at University Medical Center Groningen, Department of Medical Microbiology, Division of Clinical Viroloy, The Netherlands - has talked about the developing trends in molecular diagnostics and the impact on the Laboratory.
To learn more, please visit www.waidid.org!
COVID-19 Product Development and Clinical Trials: Considerations from Europea...Medpace
Join experts from Medpace’s regulatory and operational teams in this webinar as they provide insights and considerations on how to accelerate product development for COVID-19 during different stages
Considerations for the Next Wave of COVID-19 DevelopmentMedpace
What did we learn from the first wave of COVID-specific studies that can be applied to those studies that will follow? Medpace has gathered some of its medical and operational team experts who have been on the front-line in designing and conducting trials for SARS-CoV-2 to answer some frequently asked questions, trends they see emerging and considerations for future development.
MicroBioDx - Turnkey In Office PCR Labs with UTI, RPP and MoreMaxiMedRx
Many practices are still using offsite laboratories to process their patients Respiratory and Urinary Tract related cultures. The Point of Care PCR Joint Venture Program is revolutionizing the way both small and large practices increase monthly revenue. Often these facilities are not only billing the insurance carrier, they also send patients to collections. The Integration of this system will grant you billing privileges and the control of your patient’s financial outcome.
Digital Solutions putting the patient at the forefront of Risk ManagementMyMeds&Me
Capturing relevant, essential and complete data at the first interaction
Why surfacing targeted questions and FAQs in-stream maximises the value of the initial contact and reduces low-value follow up.
Digital solutions ensure your REMS and RMP commitments are met with appropriate evidence
Quality Control for Point of Care Testing - White PaperRandox
Point of care testing (POCT) refers to testing that is performed near or at the site of a patient with the result leading to a possible change in the care of the patient. Over the past few years, the popularity and demand of POCT has been growing rapidly. This should come as no surprise as there are many advantages to POCT, for example, the added convenience of being able to obtain a rapid result at the patient’s bedside, thus allowing immediate action, saving time and improving the potential outcome for the patient.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
Customized Oncology Development Solutions: Clinical Trials Designed Around You®Covance
Oncology is one of the most research-intensive therapeutic areas, yet no two development programs are the same. No two trials are the same. Each one calls for a customized strategy and distinct trial management approach. Covance develops fit-for-purpose solutions Designed Around You® that enable more efficient clinical trials and focus on what is most valuable to your organization.
POINT-of-IMPACT testing. A European perspective - Bert NiestersWAidid
At SoGat meeting 2019 Bert Niesters - Professor in Molecular Diagnostic in Clinical Virology, Medical Molecular Microbiologist at University Medical Center Groningen, Department of Medical Microbiology, Division of Clinical Viroloy, The Netherlands - has talked about the developing trends in molecular diagnostics and the impact on the Laboratory.
To learn more, please visit www.waidid.org!
COVID-19 Product Development and Clinical Trials: Considerations from Europea...Medpace
Join experts from Medpace’s regulatory and operational teams in this webinar as they provide insights and considerations on how to accelerate product development for COVID-19 during different stages
Considerations for the Next Wave of COVID-19 DevelopmentMedpace
What did we learn from the first wave of COVID-specific studies that can be applied to those studies that will follow? Medpace has gathered some of its medical and operational team experts who have been on the front-line in designing and conducting trials for SARS-CoV-2 to answer some frequently asked questions, trends they see emerging and considerations for future development.
MicroBioDx - Turnkey In Office PCR Labs with UTI, RPP and MoreMaxiMedRx
Many practices are still using offsite laboratories to process their patients Respiratory and Urinary Tract related cultures. The Point of Care PCR Joint Venture Program is revolutionizing the way both small and large practices increase monthly revenue. Often these facilities are not only billing the insurance carrier, they also send patients to collections. The Integration of this system will grant you billing privileges and the control of your patient’s financial outcome.
Dr. Steve Solomon - Metrics and Decision-Making for Antibiotic Stewardship in...John Blue
Metrics and Decision-Making for Antibiotic Stewardship in Human Medicine - Dr. Steve Solomon, Centers for Disease Control & Prevention, Currently serves as Director of the Office of Antimicrobial Resistance in the Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, in the Office of Infectious Diseases at CDC., from the 2014 NIAA Symposium on Antibiotics Use and Resistance: Moving Forward Through Shared Stewardship, November 12-14, 2014, Atlanta, Georgia, USA.
More presentations at http://www.swinecast.com/2014-niaa-antibiotics-moving-forward-through-shared-stewardship
Cellgen Diagnostics is an early stage venture that is developing a break through Companion Diagnostic platform that will enable Precision Medicine by determining whether a patients genetic profile is a match for the prescribed cancer therapeutic.
Tackling the U.S. Healthcare System’s Infectious Disease Management ProblemViewics
The United States healthcare system has a serious infectious disease management problem. The antibiotic resistance crisis is widespread, serious, costly, and deadly. Delays in pathogen identification lead to poor clinical outcomes, including increased mortality risk. And, optimally managing outbreaks is critical to health systems whose reimbursement is tied to the health of a population, such as ACOs.
Eleanor Herriman, MD, MBA, Chief Medical Informatics Officer at Viewics led an informative panel discussion with industry leaders on the issues surrounding the infectious disease management crisis. Margret Oethinger, MD, Ph.D., Medical Director of Providence Health & Services, and Susan E. Sharp, Ph.D., DABMM, FAAM, Regional Director of Microbiology and the Molecular Infectious Disease Laboratories, Department of Pathology, Kaiser Permanente and President-Elect, American Society for Microbiology cover the current state of infectious disease management in the U.S., and what can be done to improve it.
You’ll learn about:
• The magnitude of the U.S. health system’s infectious disease management problem
• The most serious concerns and trends for healthcare institutions and communities across the nation
• The most promising solutions to health systems’ most urgent infectious disease management challenges
MicroGuide app, pop up uni, 1pm, 3 september 2015NHS England
Expo is the most significant annual health and social care event in the calendar, uniting more NHS and care leaders, commissioners, clinicians, voluntary sector partners, innovators and media than any other health and care event.
Expo 15 returned to Manchester and was hosted once again by NHS England. Around 5000 people a day from health and care, the voluntary sector, local government, and industry joined together at Manchester Central Convention Centre for two packed days of speakers, workshops, exhibitions and professional development.
This year, Expo was more relevant and engaging than ever before, happening within the first 100 days of the new Government, and almost 12 months after the publication of the NHS Five Year Forward View. It was also a great opportunity to check on and learn from the progress of Greater Manchester as the area prepares to take over a £6 billion devolved health and social care budget, pledging to integrate hospital, community, primary and social care and vastly improve health and well-being.
More information is available online: www.expo.nhs.uk
Dr. Lauri Hicks - One Health Antibiotic Stewardship Human Health ExamplesJohn Blue
One Health Antibiotic Stewardship Human Health Examples - Dr. Dawn Sievert, Associate Director for Antimicrobial Resistance, Division of Foodborne, Waterborne, and Environmental Diseases, CDC; Dr. Edward J. Septimus, V.P. Research & Infectious Diseases, Hospital Corporation of America; Dr. Lauri Hicks, Director, Office of Antibiotic Stewardship, CDC, from the 2017 NIAA Antibiotic Symposium - Antibiotic Stewardship: Collaborative Strategy for Animal Agriculture and Human Health, October 31 - November 2, 2017, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2017-niaa-antibiotic-symposium-antibiotic-stewardship
Webinar: Defeating Superbugs: Hospitals on the Front Lines Modern Healthcare
About the Webinar: Defeating Superbugs: Hospitals on the Front Lines
http://www.modernhealthcare.com/article/20140917/INFO/309179926
Hospitals across the country are facing a grim reality in which some of the most deadly healthcare-associated infections they encounter are untreatable with first- or even second-line antibiotics. These “superbugs” affect at least 2 million Americans each year and lead to 23,000 deaths. And their threat is growing, public health officials warn. This editorial webinar and “Defeating Superbugs” white paper will explore the steps providers must take to ramp up surveillance efforts, promote appropriate antibiotic use and control outbreaks. Our panel of experts will share their organizations' experiences as well as proven strategies for success.
Registration for this webinar includes Modern Healthcare's “Defeating Superbugs” white paper, with proven tips and strategies for promoting appropriate antibiotic use, improving infection surveillance, identifying drug-resistant infections and dealing with outbreaks.
KEY TAKEAWAYS
- Best practices for effective antimicrobial stewardship
- Real-world examples of effective interventions, including universal rapid testing for drug-resistant MRSA
- Tips for engaging senior leadership
- Aggressive strategies for controlling outbreaks
PANELISTS
Lance Peterson
Director of the Clinical Microbiology and Infectious Disease Research Division
NorthShore University HealthSystem, Evanston, Ill.
Anurag Malani
Medical Director for the Infection Prevention and Antimicrobial Stewardship Programs
St. Joseph Mercy Hospital, Ann Arbor, Mich.
Robert Weinstein
Chief Medical Officer for Population Health
Chairman of the Department of Medicine, Cook County Health and Hospitals System; Professor, Rush University Medical Center, Chicago
MODERATOR
Maureen McKinney
Editorial Programs Manager
Modern Healthcare
Similar to Advanced In-Office 1-hour PCR LAB - Ancillary Revenue Program (20)
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Advanced In-Office 1-hour PCR LAB - Ancillary Revenue Program
1. Advanced In-Office
PCR Testing Program
UTI • Respiratory • Sinus • Vaginitis •
Wound Care • Gastroenterology
Ancillary Revenue Opportunity
2. www.optimalhealthadvocates.com
2
The Integration of this
system will grant you billing
privileges and the control of
your patient’s financial
outcome.
IN-OFFICE POINT-OF-CARE PCR TESTING
= RAPIDLY INCREASED MONTHLY REVENUE
Our Point of Care Joint
Venture Program is
revolutionizing the way
medical practices increase
monthly revenue.
Most practices are still using off-
site laboratories to process their
patients Urinary & Respiratory
Tract related cultures. Often
these facilities are not only
billing the insurance carrier, they
also send patients to collections.
3. www.optimalhealthadvocates.com
3
TESTING BENEFITS
Test your patients in-office and get
test results during the same visit,
while traditional culture & sensitivity
tests take 24-72 hours to get results.
ELIMINATE costly last-minute surgery
cancellations due to untreated UTI or
other infection positive/untreated
results.
1-Hour Test Results
Test results will provide the antibiotic
resistance of the organism that
presents as positive in your patients
test results.
Know for sure that you are
prescribing the most effective
antibiotic for your patient.
Antibiotic Resistance Read-Out
By integrating the point-of-care
system into your office. Your medical
practice will elevate with robust
services, increased treatment
capabilities, and monthly revenue.
Test your patients on a clinical
level just like the Laboratories.
We have designed this program to be
effortless on your part.
WE PROVIDE:
• The Setup (including your CLIA license)
• The Device
• The Technician
• The Supplies
• The Billing
The Joint Venture program is a
complete turnkey opportunity. The CDC has started to mandate the use of antibiotic alternatives for long-term
managed care. By reducing the use of antibiotics patients will have less resistance when
it is truly needed.
We have created a program that keeps you compliant with monthly reports. PCR testing
will help reduce the use of antibiotics and increase your facility health score. It is only a
matter of time before it is mandated at the clinical level.
Compliant with CDC’s Antibiotic Stewardship Program
4. www.microbiodx.com ‹#›
Test results indicate within 1 hour whether
a patient requires antibiotics, thereby
affirming a provider’s decision to treat and
select the appropriate course of antibiotics,
avoiding unnecessary antibiotic treatments,
quarantine, and isolation procedures.
“Patients can be tested quickly, in-
office, prior to surgery, avoiding
costly surgery cancellations.”
“Early detection can effectively
minimize transmission of infection,
thereby preventing or more quickly
bringing an outbreak under control.”
5. www.microbiodx.com ‹#›
Advanced PCR Technology
➔ Rapid test results in under 1-hour
➔ 96% more accurate than
traditional culture testing.
(Identifies MORE bacteria than
traditional urine culture and is able to
detect more fastidious bacteria)
➔ CDC Guidelines - “If an important
clinical decision is affected by the test
result, the [Rapid influenza test kits]
result should be confirmed by a
molecular assay, such as reverse
transcription polymerase chain reaction
(RTPCR).” -CDC on Rapid Influenza Test
Kits (RIDTs)
➔ The test is unaffected by the use
of antibiotics.
Why use PCR Technology?
RPP (Respiratory Panel Testing) is a
qualitative test that will identify DNA
from respiratory viruses and bacteria
extracted from nasopharyngeal swabs
from individuals with clinical signs and
symptoms of a respiratory tract
infection. This panel employs PCR
(Polymerase Chain Reaction)
technology which is used to “amplify”
small quantities of nucleic acid into
detectable levels which leads to more
accurate results.
What is Respiratory Panel
Testing?
UTI (Urinary Tract Infection) testing
utilizes quantitative PCR (Polymerase
Chain Reaction) technology to rapidly
analyze your patient’s sample. PCR
technology precisely detects the correct
pathogen(s) and identifies antibiotic
drug resistance. This allows providers
the ability to prescribe timely and
effective treatment.
What Is Urinary Tract
Infection Testing?
6. www.optimalhealthadvocates.com
6
What does this mean for Your Practice?
Increased Clinical
Value
100%
Over-prescription of
Antibiotics
0%
Timely, actionable
results
45 MINUTES
Stop guessing and
start treating
IMMEDIATELY
No upfront cost
$0.00
SUCCESS
Just eight (8) tests a day can generate over $30K+ per month in bottom-line revenue
7. www.optimalhealthadvocates.com
7
How Does the Joint Venture Work?
We provide all the following at zero cost for you.
Daily Revenue (8) samples per day X
$620.00
=
$4,960.00
Avg. Reimbursement per patient Daily revenue
Monthly Revenue $4960.00 Daily X
22
=
$109,120.00
Working days per month Monthly revenue
Cost to run
program daily
$265.00 per test daily
(Includes reagents, Tech,
billing, prior auth, software,
supplies, etc.)
X
8
=
$2,120
Tests per day Cost to run program daily
Cost to run
program monthly
$2,120.00 Daily X
22
=
$46,640
Working days per month Monthly cost to run program daily
Net revenue
Monthly revenue
$109,120.00 (Prior to
expenses)
-$46,640.00 $62,480.00
(Monthly expenses) Net revenue to the program
Your investment
cost = $0.00
50/50 Revenue Split Practice Monthly Revenue = $31,240.00
This complete turn-key system
is a lucrative opportunity for
your medical practice.
Our team gets you completely
setup.
Your office will never miss a
beat, from CLIA site certification
to training we will ensure that
your Point-Of-Care service is
ready for immediate use.
Custom Insurance Pro
Forma evaluation
FREE
CLIA Waived License
FREE
Dedicated On-site
Technician
FREE
Point-Of-Care
Testing Device
FREE
All-inclusive Billing
FREE
Contact: Jennifer Anderson
(775) 846-8293 (mobile)
jen@optimalhealthadvocates.com
7
8. www.optimalhealthadvocates.com
8
In-Office Testing Device
The program requires 6 feet of dedicated desk space and a CLIA Certificate.
CLIA licensure and ongoing compliance is part of the program and does not require any upfront costs.
Integrate the Point-Of-Care
testing device today
Increase your
monthly revenue with
no out-of-pocket expenses
Our well-known manufacturer provides hardware
for laboratories and hospitals nationwide.
9. www.optimalhealthadvocates.com
9
The Impact of UTI’s and RPP’s on Humanity
and the Healthcare System
~10 Million
Office Visits
per Year
23,000
Deaths
$13 Billion in
Costs
01 02 03
Up to 1/3 of all infections illustrate
resistance to antibiotics
Complications from UTI’s results in
9-11 days longer for each hospital
stay
Candida Albicans ⧫ Chlamydia Trachomatis ⧫ Neisseria Gonorrhoeae ⧫ Streptococcus agalactiae ⧫ Streptococcus pyogenes (Group B) ⧫ Trichomonas Vaginalis ⧫ Gardnerella vaginalis
⧫ Staphylococcus Aureus ⧫ MRSA (Methicillin resistance) ⧫ Staphylococcus saprophyticus serratia marcescens ⧫ Proteus Mirabilis ⧫ Klebsiella Pneumoniae/ Oxytoca ⧫ Acinetobacter
Baumannii ⧫ Citrobacter Freundii/Braakii ⧫ Escherichia Coli ⧫ Pseudomonas Aeruginosa ⧫ Enterococcus Faecium ⧫ Citrobacter Koseri ⧫ Class A B-lactamase; Blakpc ⧫ Class A B-
lactamase; Ctx-m Group 1 ⧫ Class B Metallo-b -Lactamase; Blandm ⧫ Vancomycin-resistant enterococci; VanA ⧫ DNA/RNA Amplified Probe
UTI Pathogen Panel
10. www.optimalhealthadvocates.com
10
It has been estimated each
year in the United States
the flu result in:
RESPIRATORY
BURDEN
31.4 Million
Outpatient Visits
About 200,000
Hospitalization
More than $87 Billion
in Total Economic
Burden
Between 3,000 to
49,000 Deaths
Influenza virus, (A & B) ⧫ Human metapneumovirus (A & B) ⧫ Rhinovirus species (A & B) ⧫ Adenovirus species ⧫ Parainfluenza virus species (type 1-4) ⧫ Coronavirus species
(229E, HKU1, NL63, OC43) ⧫ Legionella Pneumophila ⧫ Mycoplasma Pneumoniae ⧫ Chlamydia Pneumoniae ⧫ Streptococcus, Group A ⧫ RSV, (A & B) ⧫ Enterovirus species ⧫
Staphylococcus aureus ⧫ Haemophilus Influenzae ⧫ Moraxella catarrhalis ⧫ Streptococcus pneumoniae ⧫ Bordetella pertussis ⧫ Staphylococcus epidermidis ⧫ Klebsiella
pneumoniae ⧫ MRSA ⧫ Pneumocystis jirovecii ⧫ Coxiella Burnetii Antimicrobial Resistant Genes ⧫ VIM ⧫ CTX-M
RPP Pathogen Panel
11. www.optimalhealthadvocates.com
11
The Process
➔Complete Practice Pre-
Qualification Application
➔Schedule Call to Review
CPT codes
➔Receive Approval Letter &
Custom Proforma for your
Practice
➔Schedule meeting to
review Pro Forma & Next
Steps
➔Review Proforma with
Practice
➔Agreement and Credit
App Signatures
➔Schedule Licensing,
Validation, and
Implementation dates
➔Schedule Implementation
meeting
➔Onsite CLIA Licensing
and Validation
➔Onsite Implementation
Running Tests
Any questions please contact your Account Executive.
Day
30
Pre-Qualify